
    
      The trial is a Phase 1, open-label study to assess the safety and tolerability of
      incorporating clofarabine into an intensive chemotherapy regimen of etoposide,
      cyclophosphamide, PEG-asparaginase, and vincristine. Patients enrolled in this study will
      receive a maximum of 2 cycles of the 5-drug regimen, then will be treated according to
      investigator discretion. After the study treatment period, all patients will be followed for
      a minimum of 4 months beyond the final study visit. This study will include a maximum of 12
      evaluable patients.
    
  